NYSE · ABBVHealthcarePharmaceuticals

ABBVIE financials

$263.29−1.12%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
FY18
Dec 31
FY17
Dec 31
FY16
Dec 31
Revenue$61.16B$56.33B$54.32B$58.05B$56.20B$45.80B$33.27B$32.75B$28.22B$25.64B
Gross profit$42.96B$39.43B$33.90B$40.64B$38.75B$30.42B$25.83B$25.04B$21.17B$19.81B
Gross margin70.2%70.0%62.4%70.0%69.0%66.4%77.6%76.4%75.0%77.3%
Operating income$14.83B$9.13B$12.58B$18.12B$17.92B$11.36B$12.98B$6.88B$9.54B$9.34B
Net income$4.19B$4.24B$4.82B$11.84B$11.47B$4.56B$7.84B$5.66B$5.28B$5.92B
Net margin6.8%7.5%8.9%20.4%20.4%9.9%23.6%17.3%18.7%23.1%
Diluted EPS$2.36$2.39$2.72$6.63$6.45$2.72$5.28$3.66$3.30$3.63
EBITDA$27.99B$20.27B$22.05B$27.28B$27.57B$19.21B$15.38B$9.07B$11.37B$10.73B
Operating cash flow$19.03B$18.81B$22.84B$24.94B$20.10B$17.59B$13.32B$13.43B$9.96B$7.04B
Free cash flow$17.82B$17.83B$22.06B$24.25B$19.31B$16.79B$12.77B$12.79B$9.43B$6.56B
Diluted shares1,773.0M1,773.0M1,773.0M1,778.0M1,777.0M1,673.0M1,484.0M1,546.0M1,603.0M1,631.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$5.23B$5.52B$12.81B$9.20B$9.75B$8.45B
Short-term investments$0.00$31.0M$2.0M$28.0M$84.0M$30.0M
Total debt$67.50B$67.14B$59.38B$63.27B$76.68B$86.06B
Total assets$133.96B$135.16B$134.71B$138.81B$146.53B$150.56B
Total liabilities$137.19B$131.80B$124.31B$121.52B$131.09B$137.47B
Shareholders' equity-$3.23B$3.36B$10.40B$17.29B$15.44B$13.10B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology